Spexib 150mg Capsule, containing ceritinib, treats anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The FDA approved it for both previously treated and untreated patients. Additionally, it provides an effective alternative to conventional chemotherapy. For clinical insights, visit Mayo Clinic and Drugs.com.

Key Benefits & Uses

• Targeted Therapy: Spexib inhibits the ALK protein, which drives cancer cell growth in ALK-positive NSCLC. Researchers can explore studies on PubMed and WebMD.

• First-Line Treatment: Furthermore, doctors can prescribe it as first-line therapy for ALK-positive metastatic NSCLC, offering higher efficacy than traditional chemotherapy. For global guidelines, see WHO.

• Convenient Oral Dose: Patients take it once daily with food, which simplifies treatment. Learn about safety at Healthline.

How to Use

• Dosage: Take 450 mg once daily with food.

• Missed Dose: If you miss a dose by less than 12 hours, take it immediately; otherwise, continue with your next scheduled dose. Consult your doctor or Drugs.com for guidance.

Important Safety

Inform your doctor about liver, heart, or lung conditions before starting Spexib. Regular monitoring for liver function and heart rhythm changes is essential. Find detailed safety guidance at FDA and Mayo Clinic.

Common Side Effects

Patients may experience nausea, diarrhea, fatigue, and elevated liver enzymes. More severe effects, such as liver problems or heart rhythm disturbances, can occur. Check WebMD for complete side effect information.

Why Choose Spexib

Spexib combines targeted efficacy, convenient oral dosing, and strong clinical outcomes. Consequently, it remains a reliable choice for patients seeking modern cancer therapies. For ongoing research and updates, visit PubMed and WHO.